Hugel said it recorded the largest second quarterly earnings in its history, thanks to strong sales from its botulinum toxin, fillers, and cosmetic lineup.

The company's sales and operating profit for the second quarter was 81.6 billion won ($61.9 million) and 21.4 billion won, both up 28 percent compared to the same period in 2022.

Sales of its botulinum toxin drug Botulax (export name: Letybo) grew 17 percent compared to the second quarter of last year as it grew in both domestic and overseas markets.

In Korea, the company expanded its distribution channels online to consolidate its leading position, while overseas, Letybo continued to grow strongly in Asian markets such as Thailand, Taiwan, and Japan, and completed entry into 23 European countries.

Sales of hyaluronic acid fillers (The Chaeum and Byryzn Skinbooster HA) also grew 43 percent compared to the same period last year.

Domestic sales of The Chaeum have grown rapidly by 103 percent, thanks to expanded advertising campaigns for consumers and academic promotions, with sales gradually increasing in Asia Pacific and major European countries such as France, Poland, Germany, and the U.K.

The derma cosmetics brand Wellage has also added new online distribution and marketing channels to existing health and beauty stores and home shopping, with sales surging 41 percent year-on-year.

In the second half of the year, Hugel plans to expand its domestic market share through differentiated sales and marketing.

The company will also focus on expanding overseas markets, such as China and Australia.

The company's primary focus is to accelerate its entry into the North American botulinum toxin market.

In Canada, where the company obtained approval last year, it plans to prepare for local launch in the third quarter, and in the U.S., the company plans to resubmit its biologics license application (BLA) at the end of August and aims to obtain approval in the first quarter of next year.

"We have achieved solid sales growth in both domestic and global markets, breaking the record for the largest sales and operating profit in the second quarter ever," a Hugel official said. "In the near future, we will continue our global expansion by finalizing our entry into major overseas markets such as Canada and the U.S."